Efficacy of Tirzepatide Dual GIP/GLP‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study
Open Access
- 13 February 2025
- journal article
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (2) , e70019
Abstract
Introduction: Idiopathic intracranial hypertension (IIH) is a neurological disorder characterised by elevated intracranial pressure (ICP), predominantly affecting obese women of reproductive age. While GLP‐1 receptor agonists have shown promise in IIH management, the potential of dual GIP/GLP‐1 receptor activation through tirzepatide remains unexplored. This study aimed to evaluate tirzepatide's efficacy as an adjunctive therapy in IIH management.Methods: We conducted a retrospective cohort analysis using the TriNetX Global Health Research Network, analysing data through November 2024. Through propensity score matching, we compared 193 tirzepatide‐exposed IIH patients with 193 controls receiving standard care. Primary outcomes included papilledema severity, visual function, headache frequency, and treatment resistance, monitored at multiple follow‐up timepoints.Results: Our analysis revealed significant improvements across all measured outcomes in the tirzepatide group. At 24 months, we observed a 68% reduction in papilledema risk (RR 0.320, 95% CI 0.189–0.542, p < 0.001), a 73.9% reduction in visual disturbance and blindness risk (RR 0.261, 95% CI 0.143–0.477, p < 0.001), and a 19.7% reduction in headache risk (RR 0.803, 95% CI 0.668–0.966, p = 0.019). The tirzepatide group demonstrated significant body‐mass index reductions, reaching −1.147 kg/m2 (95% CI [−1.415, −0.879], p < 0.001) at 24 months compared to controls.Conclusions: Our results demonstrate that tirzepatide, when used as an adjunctive therapy, provides significant therapeutic benefits in IIH management, particularly in improving papilledema and visual outcomes. Our findings suggest that dual GIP/GLP‐1 receptor activation may offer advantages over traditional single‐receptor therapies, potentially through enhanced metabolic regulation and direct effects on ICP dynamics.Keywords
All Related Versions
Funding Information
- Qatar National Library
- National Center for Advancing Translational Sciences (UM1TR004400)
This publication has 26 references indexed in Scilit:
- A global federated real-world data and analytics platform for researchJAMIA Open, 2023
- The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trialBrain, 2023
- Morphological alterations of the hypothalamus in idiopathic intracranial hypertensionTherapeutic Advances in Chronic Disease, 2022
- Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertensionEuropean Journal of Endocrinology, 2022
- The Potentially Modifiable Risk Factor in Idiopathic Intracranial HypertensionNeurology Clinical Practice, 2021
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryNeuro-Oncology, 2021
- Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertensionJCI Insight, 2021
- Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic InterventionJournal of Neuro-Ophthalmology, 2018
- Evidence for potential involvement of pro-inflammatory adipokines in the pathogenesis of idiopathic intracranial hypertensionCephalalgia, 2016
- Understanding idiopathic intracranial hypertension: mechanisms, management, and future directionsThe Lancet Neurology, 2016